When a Medication Outlives Its Purpose

Every hospice admission comes with a medication list. It is often a long one, with medications added by different prescribers over time. Somewhere on it are usually a few medications that no longer fit the patient, and sometimes one or two that have a clinically appropriate alternative the hospice could cover instead.

Reviewing that list, and acting on what it shows, is deprescribing. It is one of the most ordinary things a hospice does and one of the easiest to let slide.

The clinical case stands on its own

The case for deprescribing is clinical before it is anything else. A long medication list is not a neutral thing to carry. Every added medication is another potential pill to swallow for someone who may be finding swallowing hard, another chance for a side effect, and another interaction with everything else on the list. Drug-drug and drug-allergy interactions multiply with each medication, and the sheer size of a regimen is itself a source of discomfort.

Some of those medications are no longer doing what they were prescribed to do, or have started working against the patient's comfort-focused goals of care. A drug that made sense for a specific condition can later add side effects without adding comfort. Deprescribing is the clinical judgment that a medication's burden has come to outweigh its benefit for this patient, and acting on that judgment is care, not the absence of it.

None of this is about doing less for someone. It is about not making them carry what no longer helps.

Who catches it, and when

In practice the whole care team takes part. Nurses are often the ones having the conversation at the bedside, physicians make the call, and managers and others help spot the candidates in the first place. No single role owns it.

When it happens depends on the organization. Some flag the medications at admission, during the first review of the profile. Elsewhere, the review waits until a physician can sit down with the chart, which can take days. The new requirements around what a hospice covers, and must put in writing, give every hospice a reason to make that review happen sooner rather than later.

The one decision that eases pressure from two directions

The clinical case is reason enough on its own. What makes deprescribing unusual is that the cost-conscious move and the right clinical call are, for once, the same move.

A hospice faces medication pressure from two directions. On one side, the per diem is a fixed payment, and it has to absorb every drug related to the terminal illness. The FY2027 update raised it 2.3%, and a medication that is not helping the patient is simply cost sitting against a fixed rate. On the other side, moving a drug out to Medicare Part D to get it off the hospice's books is exactly the kind of non-hospice spending the SSVI now scores and the payment-pattern report tracks, where five of its fifteen target areas watch medications billed outside the benefit.

Deprescribing answers both at once. A medication that has been stopped is not absorbed under the per diem and not billed to Part D, because it is no longer there to be paid for by anyone. The clinical decision and the financial one point the same direction, which is not usually how this works.

Finding the opportunity is the easy part

In most hospices, deprescribing breaks down at the same place: the opportunity gets identified and then nothing happens. A nurse or a pharmacist notes a medication worth stopping, it comes up in a meeting, and three weeks later the patient is still on it. The list was right, but the follow-through never came.

Spotting the candidate is the easy part. The hard part is everything after: having the conversation with the patient and family with the right information in hand, making the change, and then knowing whether it actually happened. That last part is where most teams have the least visibility. It is easy to see which medications were flagged, and much harder to see how many were actually discontinued, how long it took, and where follow-through breaks down.

The question is worth asking of your own organization:

This is where MerlinRx works. Not on finding the opportunities, which your clinicians already do, but on the part that usually falls apart: putting the right information in front of the team when the conversation happens, and making follow-through something you can see and account for rather than something you hope occurred. The measure of a deprescribing effort is not how many opportunities you spotted. It is how many you carried through.

When a medication outlives its purpose, stopping it is the uncommon decision that serves the patient and the benefit at the same time. Spotting the opportunity was never the hard part. The hard part is carrying it through.